ALT

Altimmune, Inc.
CAPPED RATING

Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It has two vaccine delivery platforms, RespirVec and Densigen.

Altimmune, Inc. (ALT) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F). The rating has held at D+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.6 / 5.0
D+
Value
F
Factor Score 0.0 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.2
EV / EBITDA -0.7
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -47.5%
Price Return 12M -61.6%
Catalyst Signal 0.00
Market Cap $303.6M
TTM Revenue $26.0K
Price / Sales 11.7K
ROE -33.2%

Historical Factor Score Progression

Held D+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 F (0.0) D+ (1.6) C- (2.1) D+ (1.6) C+ (2.6) D+ (1.6)
2026-11-10 F (0.0) D+ (1.6) C- (2.1) C- (2.0) C+ (2.6) D+ (1.7)
2026-11-03 F (0.0) D+ (1.5) C- (2.1) C- (2.0) C+ (2.7) D+ (1.7)
2026-10-27 F (0.0) D+ (1.5) C- (2.1) C (2.2) C+ (2.6) D+ (1.7)
2026-10-20 F (0.0) D+ (1.5) C- (2.1) C (2.2) C+ (2.6) D+ (1.7)
Page 1 of 8
…